Stryker
Preis: 305.64Unternehmen und Geschäftsmodell
Stryker Corporation is a leading medical technology company that develops and manufactures a range of products in the healthcare sector. Its core offerings include surgical equipment, orthopedic implants, neurotechnology, and spine products. Major business segments consist of Orthopedics, MedSurg, and Neurotechnology & Spine. The primary revenue sources are derived from sales of surgical instruments, implants, and related services.
Anlageprofil
The investment profile of Stryker is more aligned with value investors, given its current dividend yield and established market presence. However, recent revenue declines and earnings surprises may indicate challenges in growth potential. The stock may appeal to those seeking stability rather than aggressive growth.
Fundamentale Kennzahlen (experimentell)
- EPS (TTM) — Gewinn pro Aktie der letzten 12 Monate, $
- 8.73 OK
- Umsatz QoQ — Umsatzwachstum im Quartalsvergleich
- -16.1% ↓
- EPS-Überraschung
- -12.8% schlechter als erwartet
- 20d Volatilität
- 1.7% stabil
- Dividendenrendite
- 1.4% moderat letzter Ex-Tag: 2026-06-30
Prognoseauswirkung
negativIm Portfolio verfolgen
Preischart
| Datum | Vorher | Nachher | Grund |
|---|---|---|---|
| 2026-05-10 02:45 | Halten | Verkaufen | scenario_deterioration |
| 2026-05-08 15:19 | — | Halten | Weak fundamentals and negative momentum indicate high risk. |
| 2026-05-08 06:38 | Halten | Halten | Компания Stryker демонстрирует значительное снижение выручки и негативные тренды на фондовом рынке, что указывает на высокие риски для инвесторов. Учитывая текущие показатели и негативные прогнозы, рекомендуется рассмотр |
| Datum | Analyst | Action | Ziel | Preis damals |
|---|---|---|---|---|
| 2026-06-05 09:16 | Leerink Partners | Ziel gesenkt | — → 407 | 301.21 |
| 2026-05-04 13:39 | Truist Financial | Ziel gesenkt | 380 → 330 | 293.44 |
| 2026-05-04 09:27 | Barclays | Ziel gesenkt | 469 → 394 | 294.73 |